GPX3 and rheumatoid arthritis: GPX3 neutralizes ROS produced by activated neutrophils in the synovial fluid, and the dysregulation of GPx3 exacerbates chronic inflammation and immune dysfunction, highlighting its potential as a therapeutic target in RA [156].